Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc-/+ mice

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Karim, Baktiar O ^a   Rhee, Ki Jong ^b   Liu, Guosheng ^a   Zheng, Dongfeng ^a   Huso, David L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Yonsei University Wonju   (South Korea)

Author keywords

Apc; Cdk4 inhibition; Chemoprevention; Silibinin

Indexed keywords

APC PROTEIN; CYCLIN DEPENDENT KINASE 4; RETINOBLASTOMA PROTEIN; SILIBININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; IN VIVO STUDY; INTESTINE TUMOR; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN PHOSPHORYLATION;

ADENOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; DISEASE MODELS, ANIMAL; FEMALE; GENES, APC; HUMANS; KI-67 ANTIGEN; MICE; MICE, KNOCKOUT; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; SILYMARIN;

EID: 84875344694     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-157     Document Type: Article

References (47)

1. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24(11):1770-1783. 10.1200/JCO.2005.03.7689, 16603719.
2. Shi MD, Lin HH, Lee YC, Chao JK, Lin RA, Chen JH. Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide. Chem Biol Interact 2008, 174(3):201-210. 10.1016/j.cbi.2008.06.006, 18619950.
3. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001, 10(7):721-733. 10.1093/hmg/10.7.721, 11257105.
4. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D. Identification of FAP locus genes from chromosome 5q21. Science 1991, 253(5020):661-665. 10.1126/science.1651562, 1651562.
5. Lamlum H, Ilyas M, Rowan A, Clark S, Johnson V, Bell J, Frayling I, Efstathiou J, Pack K, Payne S. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat med 1999, 5(9):1071-1075. 10.1038/12511, 10470088.
6. Van der Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Van de Wetering M, Marra G. The intestinal Wnt/TCF signature. Gastroenterology 2007, 132(2):628-632. 10.1053/j.gastro.2006.08.039, 17320548.
7. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998, 281(5382):1509-1512.
8. Heinen CD, Goss KH, Cornelius JR, Babcock GF, Knudsen ES, Kowalik T, Groden J. The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology 2002, 123(3):751-763. 10.1053/gast.2002.35382, 12198702.
9. Wilkins JA, Sansom OJ. C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res 2008, 68(13):4963-4966. 10.1158/0008-5472.CAN-07-5558, 18593890.
10. Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, O'Connell BC, Mateyak MK, Tam W, Kohlhuber F. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci 2000, 97(5):2229-2234. 10.1073/pnas.050586197, 15783, 10688915.
11. Sherr CJ. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 1995, 107(2):181-186.
12. Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res 1997, 57(1):169-175.
13. Zhang T, Nanney LB, Peeler MO, Williams CS, Lamps L, Heppner KJ, DuBois RN, Beauchamp RD. Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Res 1997, 57(9):1638-1643.
14. Pan MH, Lai CS, Wu JC, Ho CT. Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compounds. Mol Nutr Food Res 2011, 55(1):32-45. 10.1002/mnfr.201000412, 21207511.
15. Su MT, Venkatesh TV, Bodmer R. Large- and small-scale preparation of bacteriophage lambda lysate and DNA. Biotechniques 1998, 25(1):44-46.
16. Shan BE, Wang MX, Li RQ. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest 2009, 27(6):604-612. 10.1080/07357900802337191, 19440933.
17. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res 2007, 143(1):58-65. 10.1016/j.jss.2007.03.080, 17950073.
18. Choi HJ, Lim Do Y, Park JH. Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3'-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol 2009, 9:39. 10.1186/1471-230X-9-39, 2700124, 19480695.
19. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989, 9(1):105-113.
20. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat med 2009, 15(9):1016-1022. 10.1038/nm.2015, 3034219, 19701202.
21. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999, 19(10):7011-7019. 84696, 10490638.
22. Whitehead RH, Demmler K, Rockman SP, Watson NK. Clonogenic growth of epithelial cells from normal colonic mucosa from both mice and humans. Gastroenterology 1999, 117(4):858-865. 10.1016/S0016-5085(99)70344-6, 10500068.
23. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003, 124(3):762-777. 10.1053/gast.2003.50094, 12612914.
24. Hirano S, Kataoka K. Histogenesis of the mouse jejunal mucosa, with special reference to proliferative cells and absorptive cells. Arch Histol Jpn 1986, 49(3):333-348. 10.1679/aohc.49.333, 3800596.
25. Kaur P, Potten CS. Cell migration velocities in the crypts of the small intestine after cytotoxic insult are not dependent on mitotic activity. Cell Tissue Kinet 1986, 19(6):601-610.
26. Qiu JM, Roberts SA, Potten CS. Cell migration in the small and large bowel shows a strong circadian rhythm. Epithelial Cell Biol 1994, 3(4):137-148.
27. Roberts SA, Hendry JH, Potten CS. Intestinal crypt clonogens: a new interpretation of radiation survival curve shape and clonogenic cell number. Cell Prolif 2003, 36(4):215-231. 10.1046/j.1365-2184.2003.00279.x, 12950390.
28. Bodmer R, Venkatesh TV. Heart development in Drosophila and vertebrates: conservation of molecular mechanisms. Dev Genet 1998, 22(3):181-186. 10.1002/(SICI)1520-6408(1998)22:3<181::AID-DVG1>3.0.CO;2-2, 9621426.
29. Olschwang S, Markie D, Seal S, Neale K, Phillips R, Cottrell S, Ellis I, Hodgson S, Zauber P, Spigelman A. Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J med genet 1998, 35(1):42-44. 10.1136/jmg.35.1.42, 1051185, 9475093.
30. Lefranc MP, Giudicelli V, Busin C, Bodmer J, Muller W, Bontrop R, Lemaitre M, Malik A, Chaume D. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 1998, 26(1):297-303. 10.1093/nar/26.1.297, 147225, 9399859.
31. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264(5157):436-440. 10.1126/science.8153634, 8153634.
32. Hatakeyama S, Mizusawa N, Tsutsumi R, Yoshimoto K, Mizuki H, Yasumoto S, Sato S, Takeda Y. Establishment of human dental epithelial cell lines expressing ameloblastin and enamelin by transfection of hTERT and cdk4 cDNAs. J Oral Pathol Med 2011, 40(3):227-234. 10.1111/j.1600-0714.2010.00950.x, 20923449.
33. Cui W, De Jesus K, Zhao H, Takasawa S, Shi B, Srikant CB, Liu JL. Overexpression of Reg3alpha increases cell growth and the levels of cyclin D1 and CDK4 in insulinoma cells. Growth Factors 2009, 27(3):195-202. 10.1080/08977190902863548, 19343564.
34. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003, 22(51):8271-8282. 10.1038/sj.onc.1207158, 14614451.
35. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008, 134(4):1224-1237. 10.1053/j.gastro.2008.02.012, 18395100.
36. Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res 2008, 1(5):376-384.
37. Sangeetha N, Felix AJ, Nalini N. Silibinin modulates biotransforming microbial enzymes and prevents 1,2-dimethylhydrazine-induced preneoplastic changes in experimental colon cancer. Eur J Cancer Prev 2009, 18(5):385-394. 10.1097/CEJ.0b013e32832d1b4f, 19654488.
38. Gershbein LL. Action of dietary trypsin, pressed coffee oil, silymarin and iron salt on 1,2-dimethylhydrazine tumorigenesis by gavage. Anticancer Res 1994, 14(3A):1113-1116.
39. Rajamanickam S, Velmurugan B, Kaur M, Singh RP, Agarwal R. Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res 2010, 70(6):2368-2378. 10.1158/0008-5472.CAN-09-3249, 2840193, 20215518.
40. Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, Agarwal R. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 2009, 8(8):2366-2374. 10.1158/1535-7163.MCT-09-0304, 2728169, 19638451.
41. Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia 2010, 12(5):415-424. 2864479, 20454513.
42. Kauntz H, Bousserouel S, Gosse F, Raul F. Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells. Apoptosis 2011, 16(10):1042-1053. 10.1007/s10495-011-0631-z, 21779837.
43. Watson AJ. An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol 2006, 57(2):107-121. 10.1016/j.critrevonc.2005.06.005, 16326109.
44. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996, 10(15):1945-1952. 10.1101/gad.10.15.1945, 8756351.
45. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275(5302):967-969. 10.1126/science.275.5302.967, 9020077.
46. Wang JY, Chang CC, Chiang CC, Chen WM, Hung SC. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem 2011, 113(5):1733-1743.
47. Raina K, Agarwal C, Agarwal R. Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-kappaB signaling. Mol Carcinog 2011, 52(3):195-206.